Xeljanz® (Tofacitinib?Citrate Sustained?Release Tablets) – For Research Use Only

Xeljanz® (Tofacitinib?Citrate Sustained?Release Tablets) – For Research Use Only

$2.00

Xeljanz® sustained-release tablets (11?mg, 30 tablets per bottle) are an extended-release formulation of tofacitinib citrate—an oral JAK inhibitor—approved in China (HJ20210071) by Pfizer. Used for modeling inflammation, JAK?STAT signaling, and autoimmune disease pathways in research. ?For wholesale prices, other specifications and uses, please consult our staff?

EMI starting from $0.00/month - View Plans
Compare

Description

Tofacitinib citrate is a small-molecule Janus kinase (JAK) inhibitor that blocks signaling downstream of cytokines, lessening inflammatory responses by suppressing JAK1/JAK3 pathways. The 11?mg once-daily sustained-release form achieves exposure equivalent to twice-daily immediate-release dosing. Clinically approved for rheumatoid arthritis, ulcerative colitis, psoriatic arthritis, and ankylosing spondylitis, it is widely applied in research models to study JAK?STAT-mediated inflammation, immune modulation, and pharmacokinetics of sustained-release formulations. For laboratory research use only.


Product Specifications

ParameterDetail
Product NameXeljanz® (Tofacitinib?Citrate SR Tablets)
SynonymsTofacitinib citrate extended-release; JAK inhibitor
Strength & Packaging11?mg per tablet, 30 tablets per bottle
Dosage FormExtended-release oral tablets
ManufacturerPfizer Pharmaceuticals LLC (USA)
Approval Number HJ20210071
Drug Standard Code86978718001568
BarcodeNot yet assigned
CAS Number477600?75?2
Molecular FormulaC??H??N?O·C?H?O? (tofacitinib citrate)
Molecular Weight~504.5?Da (citrate salt)

Mechanism of Action & Research Applications

Tofacitinib inhibits JAK1 and JAK3 enzymes, disrupting STAT-mediated cytokine signaling cascades crucial in autoimmune inflammation. The sustained-release tablet provides stable pharmacokinetics with once-daily dosing. Common research applications include modeling rheumatoid arthritis, ulcerative colitis, JAK-STAT pathway modulation, and dose-response pharmacodynamic studies.


Side Effects (For Reference Only in Research Models)

Reported side effects from clinical analogs include diarrhea, headache, hypertension, serious infections (e.g., TB, fungal, viral), increased risk of malignancies and thromboembolic events. These inform safety monitoring and dose-adjustment protocols in experimental designs.


Disclaimer

Xeljanz® (Tofacitinib?Citrate SR Tablets) is strictly intended for laboratory research use only. Not for human or veterinary therapeutic, diagnostic, or prophylactic use.

Additional information

Weight1 kg
Dimensions26 × 23 × 26 cm

Reviews

There are no reviews yet.

Be the first to review “Xeljanz® (Tofacitinib?Citrate Sustained?Release Tablets) – For Research Use Only”

Your email address will not be published. Required fields are marked *

EMI Options

Select at least 2 products
to compare